Race Oncology (ASX: RAC)

 
Minus Text Size Plus

A small biotech company with an advanced oncology drug designed to treat a rare form of cancer has just listed on the ASX.

This $15 million capped stock has ‘rediscovered’ an orphan drug named Bisantrene.

Bisantrene was previously approved for use in France, subjected to over 40 clinical trials globally, including Phase III trials throughout the 1980s; and had $100M to $200M spent on it before being lost in Big Pharma M&A activity.

In other words, this early stage ASX stock has captured a very late stage drug that is ready for market – and that means near term revenue potential…

The team at this ASX stock have delivered on similar strategies before, and draw on decades of experience in growing pharma business lines in both Big Pharma companies, and early stage, high growth, NASDAQ and ASX stocks.

The information in this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

This $15 million capped biotech junior has its sights set on the generation of European sales in the near term, and following FDA approval, hundreds of millions of dollars in revenue over the long term – which would bring serious value to its shareholders.

 

Latest Article

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

Jul 19, 2016

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

Read Article

Top Trending